European medical-technology companies appear to face only modest direct impact from recent geopolitical developments in the Middle East, according to a sector note from RBC Capital Markets. Analysts in the note said sales exposure to the region, energy-related expense sensitivity and freight cost pressure generally sit in low-single-digit ranges across the group of names assessed.
RBC examined a cohort that included Alcon AG, Carl Zeiss Meditec AG, Coloplast A/S, ConvaTec Group PLC, Demant A/S, GN Store Nord A/S, Koninklijke Philips N.V., Siemens Healthineers AG, Smith & Nephew PLC, Sonova Holding AG and Amplifon S.p.A. The analysis, prepared by analysts Jack Reynolds-Clark, Natalia Webster and Charles Weston, emphasized that most companies show limited sales exposure to the Middle East and that energy and freight costs are typically a small percentage of overall sales or COGS.
The bank noted that oil is an input into many of the raw materials used by these medtech companies, but also observed that oil generally represents a minor portion of total manufacturing costs. RBC said that multiple processing stages dilute the direct influence of crude prices on COGS, reducing the sensitivity of margins to oil moves.
Hedging activity is a key part of the picture. RBC reported that energy costs are largely hedged across the reviewed group. For example, Coloplast disclosed energy costs near 2% of COGS and described those costs as mostly hedged for the 2025/26 period. GN was highlighted as having freight exposure at a low-single-digit percentage of sales and noted that the company had significant hedges in place against that exposure.
ConvaTec's energy cost burden was estimated at 2% to 3% of COGS in RBC's breakdown. Siemens Healthineers reported that revenue from the Middle East accounts for less than 5% of sales overall, with only a smaller slice coming from the most severely impacted countries. Siemens additionally disclosed a potential annualised adjusted EBIT impact of roughly 2 to 4 percentage points from cost inflation before mitigations should supply chain headwinds persist, although RBC noted the company did not disclose the sales mix behind that figure.
At the company level, Smith & Nephew reported about 1.5% exposure across Middle East revenue, energy expenses and freight. Sonova's exposure to the Middle East was described as above 1% of sales and includes Israel; Sonova's energy costs were estimated at 1% to 3% of COGS. Carl Zeiss Meditec stood out as having the largest reported Middle East revenue exposure in the group at 2% to 3% of sales, with energy costs at approximately 3% of COGS.
RBC maintained Outperform ratings on Alcon, ConvaTec and Siemens Healthineers, pointing to the bank's relative preference for these names. The note said market attention on Siemens Healthineers could move toward its underlying fundamentals once there is clarity around the timing of any sell-down activity. Conversely, the bank said it remains cautious on Smith & Nephew, Philips, Coloplast, Carl Zeiss Meditec, Demant, GN and Amplifon, while expressing a 12-month preference for Sonova.
Demant's Middle East revenue exposure was pegged at about 1% of sales, with energy costs estimated at roughly 1% of COGS. RBC also flagged a sector-specific operational constraint: imaging companies can face helium supply tightness, although the brokers note that after an initial MRI installation, ongoing helium consumption typically becomes the responsibility of the customer rather than the vendor.
Implications
Overall, RBC's assessment suggests that direct revenue and cost exposures to the Middle East are modest for the European medtech group it covered, while hedging and the diluted role of oil in finished-product costs further limit near-term margin vulnerability. Still, company-specific differences in sales mix, hedging status and potential supply-chain impacts mean risks and outcomes will vary across individual names.